251 CONSUMERS ROAD, TORONTO, A6
Announces Completion of Acquisition by Hanmi Pharmaceutical
Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
Reports First Quarter 2026 Results
Announces Update on Anticipated Timing of Closing of the Plan of Arrangement
Aptose Biosciences Inc. Shareholders Approve Continuance Resolution
Leading Independent Proxy Advisory Firm Endorses Plan of Arrangement
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Suspension of Duty to File Reports
RW
Schedule 13E-3 - Going Private Transaction
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Definitive Merger Proxy Statement
PRER14A
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Amended Schedule 13E-3 - Going Private Transaction
PREM14A